Dianthus Therapeutics, Inc.
DNTH
Rank in Stocks
#4062
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Share Price
$71.45
Last synced: 2026-10-16
Market Cap
$4.00B
Change (1 day)
-4.13%
Change (1 year)
100.42%
Country
US
Trade Dianthus Therapeutics, Inc. (DNTH)
Category
Healthcare
Dividend yield history for Dianthus Therapeutics, Inc. (DNTH)
Dianthus Therapeutics, Inc. (stock symbol: DNTH) dividend yield (TTM) as of 2023-12-31: 0.00%
Average dividend yield, last 5 years : 0.00%
Average dividend yield, last 5 years : 0.00%
Dividend yield history for Dianthus Therapeutics, Inc. (DNTH) from 2016 to 2026
Dividend Yield at the end of each year (TTM)
| Year | Dividend Yield | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
Dividend yields (TTM) for similar companies or competitors
| Company | Dividend Yield | Country |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
